Yuki Yokoyama
Papers
1
Total Citations
2
H-Index
1
About
Yuki Yokoyama is a prominent figure in urologic oncology, with a focused research agenda on optimizing treatment strategies for high-risk prostate cancer. His major contributions lie in the integration of neoadjuvant chemohormonal therapy with robot-assisted laparoscopic radical prostatectomy, a field where he has pioneered evidence-based approaches to improve surgical outcomes. His landmark study, "Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group)," published in 2024, has already garnered 2 citations, underscoring its immediate relevance. This work, conducted through the MSUG94 group, provides critical insights into the safety and efficacy of combining systemic therapy with minimally invasive surgery, offering a potential paradigm shift for managing aggressive disease. Yokoyama’s research is characterized by rigorous propensity score-matched analyses, ensuring robust comparisons that inform clinical decision-making. His contributions are particularly impactful for surgeons and oncologists seeking to balance oncologic control with quality of life, making him a key voice in the evolving landscape of prostate cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1